Introduction
Co morbidity between post-traumatic stress disorder (PTSD) and major depressive disorder is common, with approximately half of people with PTSD also having a diagnosis of major depressive disorder (MDD) across diverse epidemiological samples. [1] [2] [3] [4] There are two competing explanations for this comorbidity. The first is that the comorbidity reflects imprecision in symptom classification into the two discrete categorical diagnoses. Support for this explanation would come from variability in comorbidity rates based on different versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM), as there have been changes to the number of symptoms required for diagnosis of PTSD, but not MDD. An alternative view is that the co-occurrence of PTSD and MDD represents a trauma-related phenotype that is distinct from MDD and reflects a fundamental dimension of risk for psychopathology following trauma exposure. Support for this explanation is less straightforward, but can be inferred from the research literature examining risk factors and biological correlates for the individual disorders, and where possible, for the comorbidity. This paper will review evidence for both views. It is critical to then consider treatment implications in order to determine whether existing treatments for PTSD can be effective in treating people who present with symptoms of both disorders, or rather, whether the presence of both conditions requires an altogether different approach.
DSM-III DSM-III-R/DSM-IV/DSM-IV-TR DSM-5
Re 5 and was comprised of 12 symptoms that were grouped into three clusters: Re-experiencing, Numbing, and a broad category of other symptoms. In the DSM-III-R/DSM-IV/DSM-IV-TR editions of the manual, the definition of PTSD was expanded to include 17 symptoms, grouped into three clusters. The principal revision was that several of the symptoms in the broad category were moved into the other two categories (eg, re-experiencing or avoidance) and this cluster was conceptualized as Hyperarousal. Additionally, several individual symptoms in the broad category were transformed into two symptoms, eg, one avoidance symptom became two avoidance symptoms. In the revision of DSM-IV to DSM-5 there were several changes. First, PTSD was removed from the anxiety disorders section and placed into a separate and new Trauma and Stressor-related Disorders section of the DSM. Second, the requirement that an individual experience "helplessness, fear, or horror" related to trauma exposure was eliminated. These two changes reflect the view that PTSD is no longer considered solely to be a fear-based anxiety disorder. Third, the total number of PTSD criteria was expanded from 17 to 20. Fourth, avoidance is now considered to be an essential element of PTSD, as at least one symptom of avoidance is required for diagnosis. Numbing symptoms were moved to a new and separate cluster in DSM-5 labeled Negative Alterations in Cognitions and Mood. in MDD criteria presents the opportunity to examine whether and how rates of comorbidity between the disorders change over the same time period. If the rates change substantively over the different versions, this would suggest that the comorbidity is an artifact of nosology. Only a few epidemiological studies have been reported that examined comorbidity rates of DSM-III diagnoses of PTSD and MDD and the rates vary considerably. In the North Carolina catchment area study of the Epidemiological Catchment Area (ECA) program, the rate of DSM-III depression in people with PTSD was only 4%. 10 In contrast, Shore et al 11 reported a rate of 51% comorbidity in a community sample of people who lived near the Mount St Helens eruption.
DSM-IV-TR
In the late 1980s and early 90s, large-scale and comprehensive epidemiological studies of PTSD were launched (eg, the Detroit Area Survey of Trauma 12 ). In addition, the National Comorbidity Survey was initiated in 1990. This effort assessed a broad range of current and lifetime DSM-III-R diagnoses in a nationally representative sample. Kessler and colleagues 3 reported that 47.9% of men and 48.5% of women with PTSD also had MDE, consistent with the rate reported in the Detroit Area Survey of Trauma. 1 The rate of comorbidity in the National Comorbidity Survey-Replication, which used DSM-IV diagnostic criteria for PTSD and MDD, was 42.8%. 13 It will be of great interest to see whether the rate of comorbidity between PTSD and MDD will change with the advent of DSM-5, as no studies to date have reported comorbidity rates of PTSD and MDD using DSM-5 criteria. However, in a multinational study of PTSD prevalence rates using varying criteria, the odds ratios associated with meeting criteria for a distress disorder (including MDE) in response to a traumatic exposure that also lead to PTSD, declined from 11.1 using DSM-IV to 7.8 using DSM-5 criteria. 14 The comorbidity rate between DSM-5 PTSD and the distress disorders in this study was low (5.5%) because only cases with first onset in conjunction with the focal trauma exposure were considered in the comorbidity percentage.
In sum, there is little evidence to suggest that changes in the way that PTSD has been conceptualized in DSM has appreciably affected the comorbidity rates over time, as the comorbidity rate from DSM-III-R to DSM-IV-TR has remained at about 50% in epidemiological samples. This is probably due to the fact that two of the three items that overlap (sleep disturbance and concentration difficulties) have stayed within the same cluster. Of note, most investigations consider lifetime diagnoses, rather than comorbidity based on exposure to the same traumatic experience. Several investigations have also demonstrated that eliminating the common symptoms between PTSD and mood and anxiety disorders using DSM-IV criteria does not appreciably change the prevalence of PTSD. [15] [16] [17] The DSM-5 is new, and conclusions await data based on the comorbidity rate using DSM-5 PTSD criteria. Stander and colleagues 18 recently reviewed the literature examining PTSD and MDD comorbidity. Although their focus was limited to militaryrelated PTSD, they found little support for the view that the PTSD/MDD comorbidity could be explained as an artifact of overlapping symptoms.
Evidence supporting PTSD/MDD comorbidity as a distinct trauma-related phenotype
An alternative view is that the comorbidity between PTSD and MDD represents a distinct phenotype, possibly even a subtype of PTSD. As discussed below, evidence to support this view can be inferred from the research literature examining risk factors and biological correlates of the two conditions. With respect to the phenomenology of the comorbidity, people with both PTSD and MDD report higher levels of distress and role impairment. [19] [20] [21] They also show higher impairment in neurocognitive functioning 22 and are at greater risk for suicide 20, 23 than people with PTSD only. Moreover, prognosis for people with both conditions is poorer than for either one alone. 24 Finally, there are distinct biological profiles associated with PTSD versus MDD, as reviewed below.
Risk factors associated with PTSD/MDD comorbidity
The co-occurrence of psychiatric diagnoses is the rule rather than an exception, and the high rate has been attributed to fundamental underlying dimensions or latent factors, termed internalizing versus externalizing. 25 The internalizing dimension is characterized by high levels of negative affectivity (also known as neuroticism) and low levels of positive affectivity (also known as extraversion) while the externalizing dimension is characterized by high levels of negative affectivity and low levels of constraint (also known as high impulsiv-ity). In general, the internalizing dimension represents a latent or underlying trait vulnerability that explains cooccurrence among mood and anxiety disorders, while the externalizing dimension underlies substance use disorders, conduct disorder, and antisocial personality disorder. PTSD is a unique disorder in that it has been shown to be related to both internalizing and externalizing dimensions in large samples of people with a diverse range of psychiatric diagnoses, 26 although see ref 27 .
Research on the latent structure of PTSD comorbidity shows that people with PTSD who report high negative affectivity and low positive affectivity are more likely to have a comorbid diagnosis of depression. 28, 29 However, people with PTSD who report high negative affectivity and low constraint are more likely to have comorbid substance-use disorders, and report higher aggression scores. 28, 29 Thus, when PTSD and MDD cooccur this may be a manifestation of the underlying vulnerability to respond to trauma with the behavioral, affective, and cognitive symptoms that reflect the internalizing dimension. That is, people who report high levels of neuroticism are prone to react to everyday stressors and challenges with anxiety, worry, irritability and sadness (ie, negative affect). This style is particularly invoked when the challenge involves loss, threat, or frustration 30 and reflects a long-standing personality dimension. Coupled with low extraversion, which refers to a tendency to seek out and enjoy social activities, the individual is less likely to ask for support from others when frustrated or upset and/or less capable of seeking novel and stimulating experiences that might be mood brightening.
Thus, when exposed to a traumatic experience, the person who develops PTSD and has an internalizing personality style is vulnerable to developing MDD. In support of this view, Spinhoven et al 31 examined the influence of neuroticism and extraversion on rates of PTSD and MDD in a longitudinal study of more than 2400 adults. The results showed that high neuroticism and low extraversion assessed at baseline were associated with development of comorbid PTSD and MDD 4 years later. Interestingly, the traits were not associated with new-onset cases of either disorder by itself, suggesting that it is the combination of high neuroticism and low extraversion that leads to the comorbidity. In contrast, the person who develops PTSD but has the externalizing personality style characterized by impulsive thoughts and behaviors is not likely to develop MDD. In this instance, PTSD is more likely to be accompanied by substance abuse and aggression. Longitudinal research is needed to better understand the structure and etiology of PTSD epidemiology.
A prominent risk factor for both PTSD and MDD is childhood adversity and abuse 32 and in the study described above, Spinhoven et al 31 reported that the relationship between the high neuroticism/low extraversion and subsequent development of comorbid PTSD and MDD was fully accounted for by retrospective reports of childhood sexual and physical abuse in multivariate analyses. A similar result was reported by Hovens et al 33 who found strong support for an association between retrospective reports of physical childhood abuse and comorbid mood and anxiety disorders in a large adult sample. In contrast, people with only an MDD diagnosis were more likely to report emotional neglect and psychological abuse in childhood. Thus, childhood maltreatment, especially physical abuse, may mediate the association between the internalizing dimension and development of MDD/PTSD. Other types of abuse may be associated with different adulthood outcomes.
In summary, epidemiological data indicate that rates of comorbidity in PTSD are higher than in other disorders, 34 suggesting that the pertinent diagnostic query is not whether PTSD is accompanied by another diagnosis, but rather, which diagnoses are also present. The combination of high negative affect and low extraversion appears to represent a pre-existing trait that confers vulnerability for the development of comorbid PTSD/ MDD, relative to other types of PTSD comorbidity. Childhood maltreatment is an important consideration in terms of understanding the etiology of PTSD comorbidity and may even mediate the association between the personality dimensions and the diagnoses. Further longitudinal research is needed to identify whether different types of childhood maltreatment are more likely to lead to internalizing versus externalizing styles of behavior, as this may provide insight into why some individuals develop PTSD/MDD while others do not.
Biological factors that distinguish between PTSD and MDD
In contrast to the risk factor research described above, biological studies that address PTSD/MDD comorbidity generally examine how PTSD and MDD have dis-C l i n i c a l r e s e a r c h tinct, and sometimes diverging, biological signals. This research includes studies that examine structural and functional neuroimaging, measures of the hypothalamic pituitary adrenal (HPA) axis, and more recently, DNA molecular markers (ie, epigenetics, gene expression).
Neuroimaging
A series of twin studies provide evidence of differences between PTSD and MDD in neuroimaging measures. In these studies, male monozygotic twin pairs were identified in which one twin was combat-exposed to the Vietnam War and developed PTSD and the cotwin was not exposed (and did not have PTSD). Twin pairs not exposed to war trauma were included as control comparison to identify vulnerability factors for the development of PTSD. In the first study, Gilbertson and colleagues 35 reported that the monozygotic twin pairs who were discordant for trauma exposure had comparable and lower hippocampal volume relative to twin pairs not exposed to war trauma. These results suggest that lower hippocampal volume is a risk factor for the development of PTSD. Drawing from the same twin sample and using the same study design, Shin and colleagues have reported that higher resting metabolic activity in the dorsal anterior cingulate cortex (ACC) and midcingulate cortex 36 and activation in the dorsal ACC during a cognitive interference task are similarly risk factors for PTSD, but not depression. In contrast, Kasai et al 37 reported lower pregenual ACC gray matter in association with PTSD and MDD. Lower gray matter was not observed in cotwins, suggesting that this measure represents an acquired characteristic of both PTSD and MDD.
Several functional imaging studies have directly compared people with PTSD and MDD to those with PTSD alone. Kemp et al 38 reported lower medial prefrontal cortex (mPFC) and amygdala activation to fearful faces in PTSD/MDD patients compared with those with only PTSD. Lanius et al 39 reported similar results in a symptom provocation paradigm, but the PTSD/ MDD versus PTSD group difference in mPFC activation did not persist after controlling for PTSD symptom severity. People in the PTSD/MDD group also had higher activation in anterior cingulate gyrus and posterior cingulate cortex and lower activation in the left insula relative to the PTSD only group, and these differences were not attenuated by PTSD symptom severity. Kennis et al 40 built upon these results by examining functional connectivity in these regions and reported higher connectivity between the subgenual ACC and perigenual ACC in patients with PTSD/MDD relative to the group with PTSD only. The PTSD/MDD group also showed lower functional connectivity between the insula and hippocampus compared with the PTSD only group. A recent review has shown that higher levels of neuroticism are related to functional activity in many of these same regions, using similar emotion-laden tasks (eg, faces). 30 Data from the twin studies suggest that some findings associated with PTSD, eg, lower hippocampal volume and higher activity in the dACC during an interference task, are risk factors that predate the development of PTSD but not MDD, while lower pregenual ACC volume is a consequence of PTSD and MDD following trauma exposure. Although only a few studies have examined neural structure and activity in people with comorbid PTSD/MDD versus those with PTSD, preliminary results suggest that fear regions (eg, amygdala, insular cortex, dACC, hippocampus, and medial PFC) and fear neurocircuitry in PTSD are more likely to be activated by threatening stimuli than they are in PTSD/ MDD. Less connectivity between the insular cortex and hippocampus in people with PTSD/MDD may reflect differences in how emotional memories are processed.
Hypothalamic-pituitary-adrenal axis
Measures that characterize the functioning of the hypothalamic-pituitary-adrenal (HPA) axis also differ in their relationships to PTSD and MDD. Both PTSD and MDD are associated with greater hypothalamic CRF release relative to healthy controls, but in people with PTSD, peripheral cortisol levels are generally lower and in MDD they are higher (reviewed in refs 41, 42) . In a direct comparison of patients with PTSD and MDD using 24-hour sampling of cortisol and chronobiological analyses, Yehuda and colleagues reported that overall cortisol levels differed between the groups, but also that the patterns of cortisol release were distinct. 43 In PTSD, there was a greater mean-to-amplitude ratio of cortisol, reflecting a greater range of cortisol release over the 24-hour cycle. In depression, the range of cortisol release was lower, relative to healthy controls. Furthermore, people with PTSD showed fewer ultradian pulses, while patients with MDD showed more ultradian pulses, re-flecting a more chaotic or less well-regulated cortisol release. Importantly, these chronobiological changes reflected central processes rather than being controlled at the level of the adrenal gland.
This distinct pattern appears to reflect differences in glucocorticoid receptor (GR) sensitivity in the two disorders, which may be a function of distinct epigenetic and molecular drivers. 21 Enhanced GR sensitivity in PTSD is inferred from results of the dexamethasone suppression test (DST), which show that people with PTSD have an exaggerated cortisol suppression response to dexamethasone (DEX). In contrast, MDD has been historically associated with cortisol non-suppression (reviewed in refs 42,44). Similar results have been observed on an in vitro measure of glucocorticoid sensitivity. 21, 44, 45 In this assay, 50% inhibition of lysozyme activity is determined by incubating cultured peripheral blood mononuclear cells (PBMCs) with varying doses of DEX. Taken together, these results indicate that in PTSD, the negative-feedback system of the HPA axis is overly sensitive. Relatively less research has examined GR sensitivity measures when PTSD and MDD co-occur, but generally, results suggest that people with PTSD/MDD resemble people with PTSD alone (eg, refs 21,43).
Molecular processes
These results can be interpreted in concert with a growing body of evidence suggesting that epigenetic processes mediate the relationship between environmental exposures and risk for psychopathology, including PTSD and MDD. 46, 47 Epigenetics refers to stable molecular changes, including DNA methylation and histone modification that regulate gene expression. With respect to psychopathology, it is thought that early-life adversity leads to such changes, which, in turn may cause life-long alterations in how genes are expressed. 48 Thus, epigenetics represents a molecular manifestation of vulnerability for psychopathology. In a recent publication, Yehuda and colleagues 21 reported that there was a unique biological signal associated with PTSD relative to trauma exposure reflecting epigenetic signaling. In this study of combat-exposed veterans, lower epigenetic methylation in the promoter region of the GR gene was associated with PTSD relative to combat-exposed veterans who did not develop PTSD, indicating that this is a marker associated with PTSD, but not exposure.
Approximately half of the veterans with PTSD also met DSM-IV diagnostic criteria for current MDD and results showed that GR gene methylation was lower in veterans with PTSD only, compared with veterans with PTSD and MDD.
Differences between PTSD and MDD with respect to FK506 binding protein 51 (FKBP5) activity have also been reported. 49 FKBP5 is a functional regulator of the GR complex; when stimulated by GR and (and other steroid receptors), FKBP5 increases in transcription and translation are associated with lower GR sensitivity. 49 Lower FKBP5 gene expression has been associated with PTSD, 50 which is consistent with higher GR sensitivity observed in this disorder. Depressive symptoms are correlated with higher FKBP5 gene expression. 49 Interestingly, the same functional variants in the FKBP5 gene interact with environmental stressors, including childhood abuse, to affect risk for adulthood PTSD and MDD (reviewed in ref 51). However, these "risk" alleles are associated with DNA methylation, gene expression, and neuroendocrine measures in directionally opposite ways in the context of PTSD and MDD. 51, 52 The opposing directionality of some of the functional and molecular findings for PTSD versus MDD suggests that studying these two genes in people with both disorders may help to understand why PTSD and MDD co-occur.
Treatment considerations
The question about why PTSD and MDD co-occur has significant implications for treatment. If the comorbidity is due to symptom overlap, then ostensibly the same treatment strategies that are effective with PTSD could be offered to people with both disorders. If the comorbidity represents a distinct phenotype or subtype of PTSD, then treatment approaches that target specific aspects of PTSD (eg, avoidance) may be less effective when the presentation includes depressive symptomatology.
Pharmacological treatment
This issue is complicated with respect to pharmacological treatment as there are no pharmacotherapies that specifically address PTSD, ie, the recommended medications are antidepressants 53 ; current guidelines for the treatment of PTSD recommend initiation of a selec-tive serotonin reuptake inhibitor (SSRI, eg, paroxetine, sertraline, or fluoxetine) or serotonin-norepinephrine reuptake inhibitor (SNRI, eg, venlafaxine). Prazosin may be added as adjunctive therapy if the presentation of PTSD includes nightmares. If the initial trial of an SSRI or SNRI is not effective after 4 to 8 weeks, consideration of another first-line SSRI/SNRI or mirtazapine is warranted. Again, Prazosin can be added as an adjunctive medication when nightmares are present. A recent meta-analysis 54 showed that the effect sizes for pharmacological treatments for PTSD are low (although comparable to effect sizes for MDD) and do not fare well relative to effect sizes for PTSD psychotherapies. With respect to PTSD/MDD comorbidity, Bernardy and Friedman 55 report that there is some evidence to suggest that people with PTSD and comorbid depression respond more poorly to antidepressants than people with PTSD alone. However, they posit that people with comorbid PTSD/MDD who also report suicidal ideation and childhood trauma exposure may account for poor response to treatment.
With respect to psychotherapies, treatment recommendations for PTSD and MDD are distinct and there are no clear guidelines for treating the comorbidity. Treatment for PTSD includes trauma-focused therapies, which if effective, will also be associated with change in symptoms of depression (reviewed in ref 56), particularly if the depression is mild in severity. Prolonged Exposure (PE) and Cognitive Processing Therapy target avoidance, now considered by DSM-5 to be essential for diagnosis. Dropout rates are high in trauma-focused treatments and are attributed to the initial increase in symptoms as patients begin describing the trauma memory, which activates an avoidance mechanism (ie, cancelling or no-showing for subsequent appointments). Dropout rates are even higher when PTSD is comorbid with depression, suggesting that strategies that specifically target depression (eg, ref 57) or increase retention may be useful in enhancing delivery of the trauma-focused interventions. Regarding retention in psychotherapy, Yehuda and colleagues 58 recently reported that hydrocortisone augmentation of PE was associated with greater improvement compared with placebo, a finding that was explained by significantly greater patient retention in the hydrocortisone augmentation treatment condition. The mechanism for such an effect is not known, but the authors proposed that hydrocortisone administration prior to a therapy session diminished the fear response associated with activation of the traumatic memory during the session. Such a mechanism could potentially decrease avoidance, thereby increasing retention in treatment.
Summary
Treatment of PTSD and comorbid MDD is complex. People with both disorders show greater social, occupational, and cognitive impairment, report higher levels of distress, and are more likely to attempt suicide. Prognosis is poor when the two disorders co-occur and treatment dropout is more common. People who respond to challenges and trauma exposures with negative affect may be particularly prone to developing both disorders and also to report childhood maltreatment. Biological evidence is beginning to suggest that this trauma-related phenotype may represent a subtype of PTSD. Further examination of the GR and FKBP5 genes and related molecular processes is warranted. Finally, new treatment strategies that target the unique psychological and biological aspects of the comorbidity are needed. o Comorbilidad entre trastorno por estrés postraumático y trastorno depresivo mayor: explicaciones alternativas y consideraciones terapéuticas 
